How UV222™Far-UVC technology Supports strict Annex 1 Sterile Manufacturing Mandates.
Now that Far-UVC light technology has become a powerful and highly effective tool against microbial contamination, pharmaceutical manufacturers are increasingly adopting UV light technology as a key component of a Contamination Control Strategy (CCS), to comply with Annex 1 guidelines.
Of particular importance to Grade A spaces in pharma manufacturing is the bioburden reduction capability of filtered UV light at the very specific wavelength of 222nm. This wavelength, embodied in the patented products from Danish Far-UVC pioneer UV Medico, is proven to be human safe. UV222™ products emit a powerful light that does not penetrate human skin or eyes. But it does inactivate airborne and surface microbes comprehensively.
Beyond immediate microbial inactivation, UV222™ has been shown to suppress the ability of microorganisms to recover after exposure, effectively preventing both light-induced and dark DNA repair mechanisms. This means no post-treatment regrowth – a critical advantage for maintaining aseptic conditions in sterile manufacturing.
That means pharma manufacturers can add an extra layer of continuous bioburden security to their operations by deploying UV222 technology in occupied spaces. Personnel are amongst the largest sources of microbial contamination. Human-safe Far-UVC solutions help to eliminate such contamination.
For example, the UV222 Booth decontaminates gowned operators before they enter a critical cleanroom environment. It revolutionises cleanroom sanitisation in under 30 seconds. In addition, the UV222 Step-On reduces contamination risks from cleanroom footwear. Install it at critical entry points in conjunction with sticky mats to rapidly decontaminate shoe soles and eliminate microbes in areas that wipes often miss.
UV222™ Far-UVC products inactivate microorganisms effectively without chemicals and continuously without requiring manual intervention in aseptic spaces. It is a safe and contactless solution.
Annex 1 mandates
EU GMP Annex 1 directives mandate strict microbial control for sterile manufacturing in pharmaceutical operations. UV222 technology support Annex 1 compliance by inactivating bacteria, viruses and fungi safely, thereby reducing contamination risks and preventing costly deviations and shutdowns. It aligns with the emphasis in Annex 1 on minimising contamination risk and maintaining aseptic conditions.
See how products in the UV222 range support Annex 1 in pharmaceutical environments:
- Decontaminating gowned personnel with the UV222 Booth.
- Continuous microbial control with UV222 Cleanroom Downlights.
- Maintaining very low bioburden levels between conventional cleaning and disinfection procedures with UV222 technology.
Key UV222 contributions to Annex 1 compliance
- Personnel Decontamination: UV222 booths rapidly decontaminate gowned operators before they enter critical zones, dramatically lowering the microbial load they carry into the cleanroom.
- Continuous Microbial Control: UV222 downlights and ceiling fixtures provide ongoing inactivation of airborne and surface microbes, maintaining a consistently low bioburden between conventional cleaning procedures and deep cleaning cycles.
- Safe for Occupied Spaces: 222nm UV light doesn’t penetrate skin or eyes, so it can be used in occupied cleanrooms to offer continuous protection without disrupting operations.
- Reduces Contamination Excursions: By proactively inactivating pathogens, it prevents microbial excursions that lead to environmental monitoring alerts, interventions and production delays.
- Aseptic Filling Lines: UV222 technology reduces microbial burden in these critical areas, which is essential to safeguard product integrity and comply with Annex 1.
Far-UVC technology effectively shifts cleanroom management away from reactive microbial detection to proactive prevention, helping pharmaceutical manufacturers to meet the stringent control requirements of Annex 1, which advocates the adoption of advanced technologies like Far-UVC.
Incorporating UV222 technology within the framework of the 2022 EU GMP Annex 1 guidelines and a robust Contamination Control Strategy sets the foundation for a future where product safety is prioritised. By embracing these innovations, pharmaceutical manufacturers can ensure compliance and achieve excellence in sterile product manufacturing.
